BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30502564)

  • 1. Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.
    Pouzoulet F; Alentorn A; Royer-Perron L; Assayag F; Mokhtari K; Labiod D; Le Garff-Tavernier M; Daniau M; Menet E; Peyre M; Schnitzler A; Guegan J; Davi F; Hoang-Xuan K; Soussain C
    Blood Cells Mol Dis; 2019 Mar; 75():1-10. PubMed ID: 30502564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
    Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
    Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of primary central nervous system and primary intraocular lymphomas.
    Tuaillon N; Chan CC
    Curr Mol Med; 2001 May; 1(2):259-72. PubMed ID: 11899075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
    Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
    Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of intracerebral lymphoma growth delineated in a syngeneic mouse model of central nervous system lymphoma.
    Montesinos-Rongen M; Sánchez-Ruiz M; Brunn A; Hong K; Bens S; Perales SR; Cigudosa JC; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2013 Apr; 72(4):325-36. PubMed ID: 23481709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?
    Kim JA; Kim SJ; Do IG; Jin J; Nam DH; Ko YH; Kim K; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):205-13. PubMed ID: 21281236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
    Kadoch C; Dinca EB; Voicu R; Chen L; Nguyen D; Parikh S; Karrim J; Shuman MA; Lowell CA; Treseler PA; James CD; Rubenstein JL
    Clin Cancer Res; 2009 Mar; 15(6):1989-97. PubMed ID: 19276270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Tim-1 in primary CNS lymphoma.
    Kishimoto W; Nishikori M; Arima H; Miyoshi H; Sasaki Y; Kitawaki T; Shirakawa K; Kato T; Imaizumi Y; Ishikawa T; Ohno H; Haga H; Ohshima K; Takaori-Kondo A
    Cancer Med; 2016 Nov; 5(11):3235-3245. PubMed ID: 27709813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective central nervous system tropism of primary central nervous system lymphoma.
    Jiang L; Marlow LA; Cooper SJ; Roemeling CV; Menke DM; Copland JA; Tun HW
    Int J Clin Exp Pathol; 2010 Oct; 3(8):763-7. PubMed ID: 21151389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
    Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
    Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
    [No Abstract]   [Full Text] [Related]  

  • 17. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
    Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
    Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.
    Ben Abdelwahed Bagga R; Donnou S; Cosette J; Sautès-Fridman C; Aouni M; Fisson S
    J Neurooncol; 2015 Jan; 121(1):9-18. PubMed ID: 25300908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
    Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.